Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. [electronic resource]
Producer: 20110426Description: 263-76 p. digitalISSN:- 1555-8576
- Animals
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Cell Survival -- drug effects
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical
- Drug Synergism
- Female
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Inhibitory Concentration 50
- Lapatinib
- Mice
- Mice, SCID
- Pentacyclic Triterpenes
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- Signal Transduction
- Trastuzumab
- Triterpenes -- administration & dosage
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.